Clinical Outcomes and Prognostic Factors of Robotic Assisted Rectal Cancer Resection Alone vs. Robotic Rectal Cancer Resection With Natural Orifice Specimen Extraction

Sponsor
Taiyuan Li (Other)
Overall Status
Completed
CT.gov ID
NCT04265417
Collaborator
(none)
98
22.8

Study Details

Study Description

Brief Summary

Robotic rectal cancer resection with natural orifice extraction is a recently developed minimally invasive surgery for patients with rectal cancer. However, it's safety and feasibility remain undiscussed and controversial. This study reported the clinical outcomes and prognostic factors of robotic assisted rectal cancer resection alone vs. robotic rectal cancer resection with natural orifice extraction to discuss aforementioned question.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Robotic Assisted Rectal Cancer Resection Alone
  • Procedure: Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction

Detailed Description

Robotic rectal cancer resection with natural orifice extraction is a recently developed minimally invasive surgery for patients with rectal cancer. However, it's safety and feasibility remain undiscussed and controversial. This study reported the clinical outcomes and prognostic factors of robotic assisted rectal cancer resection alone vs. robotic rectal cancer resection with natural orifice extraction to discuss aforementioned question. From January 2015 to November 2016, a consecutive wave of 49 patients underwent robotic rectal cancer resection with natural orifice extraction and 49 matched patients underwent conventional robotic assisted rectal cancer resection were systematically analyzed in this study.

Study Design

Study Type:
Observational
Actual Enrollment :
98 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Clinical Outcomes and Prognostic Factors of Robotic Assisted Rectal Cancer Resection Alone vs. Robotic Rectal Cancer Resection With Natural Orifice Specimen Extraction
Actual Study Start Date :
Jan 6, 2015
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
RARC group

Participants in this group underwent robotic assisted rectal cancer resection

Procedure: Robotic Assisted Rectal Cancer Resection Alone
participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.

NOSE group

Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction

Procedure: Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction
participants in this group underwent robotic rectal cancer resection,the specimens were extractd through anus and vagina.

Outcome Measures

Primary Outcome Measures

  1. Overall survival [Up to 36 months]

    To determine the survival differences between NOSE group and RARC group. Overall survival is defined as the time from surgery to death from any causes

  2. Disease-free survival [Up to 36 months]

    To determine the survival differences between NOSE group and RARC group. Disease-free survival is defined as the time from surgery to local or distant recurrence

Secondary Outcome Measures

  1. Operation time [1 day]

    To determine the differences between NOSE group and RARC group

  2. Estimated intraoperative blood loss [1 day]

    To determine the differences between NOSE group and RARC group

  3. Postoperative hospital stay [30 days]

    To determine the surgical and patients burdern differences between NOSE group and RARC group

  4. Postoperative visual analogue scale scale on day 1 [1 day]

    To determine the surgical differences between NOSE group and RARC group. Maxium sacle is 10, miniun scale is 0. 0 represents no pain. 10 represents maximun pain.

  5. Time to pass flatus [30 days]

    To determine the surgical differences between NOSE group and RARC group

  6. Hospitalization costs [30 day]

    to determine the patients burden differences between NOSE group and RARC group

  7. Specimen length [30 day]

    To determine the surgical differences between NOSE group and RARC group

  8. Proximal margin [30 day]

    To determine the pathological differences between NOSE group and RARC group

  9. Distal margin [30 days]

    To determine the pathological differences between NOSE group and RARC group

  10. Histological differentiation [30 days]

    To determine the pathological differences between NOSE group and RARC group

  11. Number of lymph nodes harvested [30 days]

    To determine the pathological differences between NOSE group and RARC group

  12. Postoperative white blood cell count [30 days]

    To determine the surgical stress response differences NOSE group and RARC group

  13. Postoperative procalcitonin [30 days]

    To determine the surgical stress response differences NOSE group and RARC group

  14. Postoperative C-reactive protein [30 days]

    To determine the surgical stress response differences NOSE group and RARC group

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. T stage 1-3;

  2. aged between 18 to 75;

  3. the tumor margin is at least 4 cm from the anus;

  4. body mass index ≤30kg/m2;

  5. no distant metastases; (6)tumor size≤5cm.

Exclusion Criteria:
  1. emergency surgery for intestinal obstruction or massive bleeding;

  2. history of abdominal or pelvic surgery.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Taiyuan Li

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taiyuan Li, Prof., Chief physician, Head of The Fifth Department of General Surgery, The First Affiliated Hospital of Nanchang University
ClinicalTrials.gov Identifier:
NCT04265417
Other Study ID Numbers:
  • RARN
First Posted:
Feb 11, 2020
Last Update Posted:
Feb 18, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2020